Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1994 3
1995 4
1996 2
1997 1
1998 1
1999 1
2000 1
2002 4
2003 4
2004 1
2005 1
2006 1
2007 2
2008 3
2009 3
2010 5
2011 16
2012 11
2013 12
2014 4
2015 7
2016 10
2017 16
2018 14
2019 7
2020 12
2021 12
2022 22
2023 18
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Results by year

Filters applied: . Clear all
Page 1
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy.
Li G, Choi JE, Kryczek I, Sun Y, Liao P, Li S, Wei S, Grove S, Vatan L, Nelson R, Schaefer G, Allen SG, Sankar K, Fecher LA, Mendiratta-Lala M, Frankel TL, Qin A, Waninger JJ, Tezel A, Alva A, Lao CD, Ramnath N, Cieslik M, Harms PW, Green MD, Chinnaiyan AM, Zou W. Li G, et al. Among authors: sankar k. Cancer Cell. 2023 Feb 13;41(2):304-322.e7. doi: 10.1016/j.ccell.2022.12.008. Epub 2023 Jan 12. Cancer Cell. 2023. PMID: 36638784 Free PMC article.
TOPAZ-1: a new standard of care for advanced biliary tract cancers?
Ebia MI, Sankar K, Osipov A, Hendifar AE, Gong J. Ebia MI, et al. Among authors: sankar k. Immunotherapy. 2023 May;15(7):473-476. doi: 10.2217/imt-2022-0269. Epub 2023 Mar 23. Immunotherapy. 2023. PMID: 36950948 No abstract available.
Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA.
Hosono Y, Niknafs YS, Prensner JR, Iyer MK, Dhanasekaran SM, Mehra R, Pitchiaya S, Tien J, Escara-Wilke J, Poliakov A, Chu SC, Saleh S, Sankar K, Su F, Guo S, Qiao Y, Freier SM, Bui HH, Cao X, Malik R, Johnson TM, Beer DG, Feng FY, Zhou W, Chinnaiyan AM. Hosono Y, et al. Among authors: sankar k. Cell. 2023 Sep 14;186(19):4254-4255. doi: 10.1016/j.cell.2023.08.025. Cell. 2023. PMID: 37714137 No abstract available.
Recent advances in the management of hepatocellular carcinoma.
Sankar K, Gong J, Osipov A, Miles SA, Kosari K, Nissen NN, Hendifar AE, Koltsova EK, Yang JD. Sankar K, et al. Clin Mol Hepatol. 2024 Jan;30(1):1-15. doi: 10.3350/cmh.2023.0125. Epub 2023 Jul 21. Clin Mol Hepatol. 2024. PMID: 37482076 Free PMC article. Review.
Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular Carcinoma.
Yeo YH, Liang J, Lauzon M, Luu M, Noureddin M, Ayoub W, Kuo A, Sankar K, Gong J, Hendifar A, Osipov A, Friedman ML, Lipshutz HG, Steinberger J, Kosari K, Nissen N, Abou-Alfa GK, Singal AG, Yang JD. Yeo YH, et al. Among authors: sankar k. Am J Gastroenterol. 2023 Dec 1;118(12):2201-2211. doi: 10.14309/ajg.0000000000002467. Epub 2023 Aug 10. Am J Gastroenterol. 2023. PMID: 37561061
The role of biomarkers in personalized immunotherapy.
Sankar K, Ye JC, Li Z, Zheng L, Song W, Hu-Lieskovan S. Sankar K, et al. Biomark Res. 2022 May 18;10(1):32. doi: 10.1186/s40364-022-00378-0. Biomark Res. 2022. PMID: 35585623 Free PMC article. Review.
180 results